Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Karina Vargova"'
Autor:
Karina Vargova, Tomas Stopka, Magali Olivier, Jiri Zavadil, S Barrin, Hana Huskova, Stephanie Villar, Michael Korenjak, Annette Weninger, Monica Hollstein, Maude Ardin, Zdenko Herceg
Publikováno v:
Oncogene
The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address thi
Autor:
Neeraj Kumar Singh, Vojtech Kulvait, Ashish Choudhary, Yashaswini S Ullal, Lubomir Minarik, Christopher R. Cogle, Anna Jonasova, Kunal Ghosh Roy, Taher Abbasi, Sirisha Narayanabhatia, Aktar Alam, Tomas Stopka, Shireen Vali, Karina Vargova, Leylah Drusbosky
Publikováno v:
Blood. 132:3087-3087
BACKGROUND: Azacitidine (AZA) is currently a drug of choice for most of high-risk MDS patients. However, only 40-50% of MDS patients achieve clinical improvement with AZA. There is a need for a predictive clinical decision support tool that can ident
Autor:
Vojtech Kulvait, Taher Abbasi, Lubomir Minarik, Krishna Kumar Tiwari, Chandan Kumar, Shireen Vali, Karina Vargova, Leylah Drusbosky, Mamatha Patil, Anna Jonasova, Christopher R. Cogle, Rakhi Purushothaman Suseela, Patil Nilesh Dattatraya, Neeraj Kumar Singh, Tomas Stopka
Publikováno v:
Blood. 132:5506-5506
BACKGROUND: TET2 (Ten-eleven-translocation-2) mutations found in 10-30% of MDS and AML patients are actionable for Azacitidine (AZA) treatment (PMID: 21828143). Although response rate of AZA in older AML patients is ~47%, rate of relapse is high due
Autor:
Anna Jonasova, Krivjanska M, Marek Trneny, Monika Belickova, Emanuel Necas, Karina Vargova, Filipp Savvulidi, Nikola Curik, Hana Hájková, Petra Vlckova, Pospisil, Cedrik Haškovec, Pavel Burda, Tomas Stopka, Jaroslav Cermak, Peter Laslo
Publikováno v:
Leukemia. 26:1804-1811
Epigenetic 5-azacitidine (AZA) therapy of high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) represents a promising, albeit not fully understood, approach. Hematopoietic transcription factor PU.1 is dynamically regulated b
Autor:
Marek Trneny, Josef Karban, Nina Dusilkova, Hana Huskova, Tomas Stopka, Katarina Korecka, Jarmila Vargova, Karina Vargova
Publikováno v:
International journal of hematology. 102(4)
The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these dat
Autor:
E Kuzmova, Peter Laslo, Libor Stanek, Ulrich Steidl, Pavel Burda, Anna Jonasova, Karina Vargova, M Dluhosova, V Pospisil, Filipp Savvulidi, Tomas Stopka, Petra Basova
Publikováno v:
Oncogene. 33(39)
PU.1 downregulation within hematopoietic stem and progenitor cells (HSPCs) is the primary mechanism for the development of acute myeloid leukemia (AML) in mice with homozygous deletion of the upstream regulatory element (URE) of PU.1 gene. p53 is a w
Publikováno v:
Frontiers in bioscience (Elite edition). 1(2)
Nucleosome movement is, at least in part, facilitated by ISWI ATPase Smarca5 (Snf2h). Smarca5 gene inactivation in mouse demonstrated its requirement at blastocyst stage; however its role at later stages is not completely understood. We herein determ
Autor:
Karina Vargova, Jarmila Vargova, Vojtech Kulvait, Anna Jonasova, Nina Dusilkova, Tomas Stopka
Publikováno v:
ResearcherID
Introduction and hypothesis: Somatic gene mutations develop in ~78% Myelodysplastic syndrome (MDS) patients. MDS progresses into an unstable phase characterized by an accumulation of myeloblasts that is indicated for the DNA demethylation therapy wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcde4b1a8e33eb60eb23344c4b6507f1
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000368021801045&KeyUID=WOS:000368021801045
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000368021801045&KeyUID=WOS:000368021801045
Autor:
Lubomir Minarik, Karina Vargova, Vojtech Kulvait, Nina Dusilkova, Anna Jonasova, Kamila Polgarova, Zuzana Zemanova, Tomas Stopka
Publikováno v:
ResearcherID
Introduction: Myelodysplastic syndromes (MDS) are clonal disorders of myeloid hematopoietic stem cells. Recent studies has shown that nearly 90% of patients with MDS carry somatic mutations in bone marrow (BM). These findings triggered a number of st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::636316c1611906b1fe60b8bb606d3746
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000394452502080&KeyUID=WOS:000394452502080
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000394452502080&KeyUID=WOS:000394452502080
Autor:
Vojtech Kulvait, Vit Pospisil, Karina Vargova, Tomas Stopka, Pavel Klener, Nina Dusilkova, Marek Trneny, Jiri Zavadil, Jarmila Vargova
Publikováno v:
ResearcherID
Mantle cell lymphoma (MCL) is a relatively distinct B-cell non-Hodgkin lymphoma subtype with aggressive and often recurrent clinical course. At diagnosis, MCL often manifests with leukemization, a feature more common to chronic lymphocytic leukemia (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05e5991d8c41344ec08f8a01f23e524a
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000394452307062&KeyUID=WOS:000394452307062
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000394452307062&KeyUID=WOS:000394452307062